Refoxy Pharmaceuticals Raises €9.1M in Seed Extension
Summary
Refoxy Pharmaceuticals, a Berlin, Germany-based preclinical biotech company developing small molecule activators of the FOXO3 transcription factor for the treatment of age-related diseases, raised €9.1M in Seed extension funding. The round was led by Boehringer Ingelheim Venture Fund (BIVF), and joined by Apollo Heath Ventures, NRW.Venture, and High-Tech Gründerfonds (HTGF). The company intends to use the funds to advance the development of new therapeutic medicines in diverse indications, starting with idiopathic pulmonary fibrosis (IPF). Co-founded by Dr. Victor Bustos and Prof. Wolfgang Link in partnership with Apollo Health Ventures, Refoxy is a biotech company developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. The company is developing a pipeline of therapeutics, with an initial focus on fibrotic disorders, particularly IPF.